
BlossomHill Therapeutics
BLSMPro trackingBlossomHill Therapeutics, Inc. · Nasdaq · Clinical-stage biotechnology · Research source · 424B4 · Research as of 2026/08/07 · Latest filing · 10-Q · 2026-11-12 SEC ↗ · SEC checked 2026-11-21
Saved research available · 424B4
BlossomHill Therapeutics offered 9,375,000 shares at $16.00 per share and expects to use net proceeds primarily for clinical development of its oncology drug candidates.
Updates and this research have separate source dates; newer facts do not silently replace earlier conclusions.
Newly listed — review valuation, deal quality and post-IPO supply before acting
A clinical-stage developer of small-molecule cancer medicines. The IPO priced at $16.00 and raised $150.00M.
Full source-backed summary
A clinical-stage developer of small-molecule cancer medicines. The IPO priced at $16.00 and raised $150.00M. The latest market-value reference is $501.94M; reported revenue is Pre-revenue and net result is $(71.09M). The offer figures are reconciled to the final prospectus.
- Business and development direction
A clinical-stage developer of small-molecule cancer medicines.
Current business Clinical-stage biotechnology100%
Future development Future direction not yet disclosed
Key risks
Risk 1
Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.
Risk 2
The latest reported period remains loss-making.
Risk 3
The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | This saved report has no compatible source inputs for this calculation. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio · calculated | Shares |
|---|---|---|---|---|
| 1 | J.P. Morgan Securities LLC | 38.00% | 3,562,500 shares | |
| 2 | Leerink Partners LLC | 28.00% | 2,625,000 shares | |
| 3 | Guggenheim Securities, LLC | 18.00% | 1,687,500 shares | |
| 4 | LifeSci Capital LLC | 9.00% | 843,750 shares | |
| 5 | H.C. Wainwright & Co., LLC | 7.00% | 656,250 shares |
Ratio = institution commitment ÷ complete source-table total (9,375,000 shares) × 100.
Underwriting terms
| Measure | Reported value | Unit |
|---|---|---|
| Underwriting discount per share | $1.12 | $ / share |
| Total underwriting discount | $10,500,000 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 7; source 2065:5902; SHA256 a88a28c81a03f8ac1d36461ffb847f8cbbc852f05965045198cca81bc9c67c4f ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 7; source 2065:5902; SHA256 a88a28c81a03f8ac1d36461ffb847f8cbbc852f05965045198cca81bc9c67c4f ↗IPO CAPITAL QUALITY
Basis and evidence
No estimate is substituted for missing offer terms.
Capital quality is not yet quantifiable from the filed terms. IPO177 will calculate it when primary/secondary shares, fees and net proceeds are all disclosed.
Offering structure
| Measure | Reported value | Unit |
|---|---|---|
| Shares offered | 9,375,000 | Shares |
| Offering price | $16 | $ / share |
| Gross offering amount | $150,000,000 | $ |
Source and calculation
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
SEC table 26 row 1; source 80140:80472; SHA256 0809dfe46127523e302b62dfe381fc27eebee8aa80610e9d127892b4a1e49ec3 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 5; source 2065:5902; SHA256 a88a28c81a03f8ac1d36461ffb847f8cbbc852f05965045198cca81bc9c67c4f ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 5; source 2065:5902; SHA256 a88a28c81a03f8ac1d36461ffb847f8cbbc852f05965045198cca81bc9c67c4f ↗Dilution and valuation
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Base post-offer valuation | ≈ 30.6437M | ≈ $490.2986M | |
| Post-offer shares — base/no option | 30,643,660 | — | |
| Post-offer shares — full option | 32,049,910 | — | |
| Capitalization shares — actual | 2,644,326 | — | |
| Capitalization shares — pro forma | 21,268,660 | — | |
| Capitalization shares — pro forma as adjusted | 30,643,660 | — | |
| Shares offered | 9,375,000 | — | |
| Offering price | — | $16 | |
| Gross offering amount | — | $150,000,000 |
Basis and evidence ↗
Prospectus share summary; Common stock to be outstanding immediately after this offering; 30,643,660 shares (or 32,049,910 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Prospectus share summary; Common stock to be outstanding immediately after this offering; 30,643,660 shares (or 32,049,910 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: actual; Common stock, $0.0001 par value; 110,000,000 shares authorized, 2,644,326 shares issued and outstanding, actual; 700,000,000 shares authorized, pro forma and pro forma as adjusted; 21,268,660 shares issued and outstanding, pro forma; 30,643,660 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma; Common stock, $0.0001 par value; 110,000,000 shares authorized, 2,644,326 shares issued and outstanding, actual; 700,000,000 shares authorized, pro forma and pro forma as adjusted; 21,268,660 shares issued and outstanding, pro forma; 30,643,660 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma as adjusted; Common stock, $0.0001 par value; 110,000,000 shares authorized, 2,644,326 shares issued and outstanding, actual; 700,000,000 shares authorized, pro forma and pro forma as adjusted; 21,268,660 shares issued and outstanding, pro forma; 30,643,660 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 30,643,660 shares (or 32,049,910 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Offering price: $16
Exact input · Post-offer shares — base/no option: 30,643,660
Prospectus share summary; Common stock to be outstanding immediately after this offering; 30,643,660 shares (or 32,049,910 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — full option: 32,049,910
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 30,643,660 shares (or 32,049,910 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 30,643,660 shares (or 32,049,910 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Prospectus share summary; Common stock to be outstanding immediately after this offering; 30,643,660 shares (or 32,049,910 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 30,643,660 shares (or 32,049,910 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — base/no option: 30,643,660
Exact input · Offering price: $16
Share-count comparison
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Source ↗IPO valuation scenario simulator
Offering completion · $16 × ≈ 30.6437M shares · Final
Source and calculation ↗
Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.
Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.
Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.
The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
These saved displays are not verified valuation inputs. Their stage, precision and assumptions have not been established by the current source.
IPO price · 9.375M · $150.00M · $16.00
Latest shares outstanding · 30.64M · $501.94M · Market snapshot
Revenue reference · — · Pre-revenue · —
Net-result reference · — · $(71.09M) · Loss-making
$16 × 30,643,660 = $490,298,560 [summary-table-28-base-1-price, summary-table-28-base-1-post]
Exact calculation · Derived whole-issuer equity value: $490,298,560
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Comparable ownership figures across stages are unavailable in this report. See Control for holdings on their disclosed basis. Open filing ↗ |
Latest available filing
- Economic
- ~30.6%*
- As of
- 2026/08/07
Relationship filters
Select for details · BlossomHill Therapeutics
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| our executive officers, directors and stockholders whoOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: owned; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group, no exercise of the underwriters’ option to purchase additional shares of our common stock and no exercise of outstanding options other than the Exercised Option Share Issuance); source scope: of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately; not an additive ownership partition |
| our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliatesOwnership as disclosed | — | approximately 41.8%Beneficial | — | Source statement; approximately ; source predicate: will, in the aggregate, hold; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group, no exercise of the underwriters’ option to purchase additional shares of our common stock and no exercise of outstanding options other than the Exercised Option Share Issuance); source scope: of our outstanding common stock (based on the number of shares of our common stock outstanding as of March 31, 2026 and assuming no purchase of shares in this offering by any of this group, no exerci; not an additive ownership partition |
| J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliatesBeneficial shares | 3,973,138 | — | — | Sharesbeneficially ownedprior to offering; Number |
| J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliatesBeneficial shares | 3,973,138 | — | — | Sharesbeneficially ownedafter offering; Number |
| Entities affiliated with Cormorant Asset Management LPBeneficial shares | 3,301,534 | — | — | Sharesbeneficially ownedprior to offering; Number |
| Entities affiliated with Cormorant Asset Management LPBeneficial shares | 3,301,534 | — | — | Sharesbeneficially ownedafter offering; Number |
| OrbiMed Private Investments VIII, LPBeneficial shares | 2,089,279 | — | — | Sharesbeneficially ownedprior to offering; Number |
| OrbiMed Private Investments VIII, LPBeneficial shares | 2,089,279 | — | — | Sharesbeneficially ownedafter offering; Number |
| Vivo Innovation Fund II Holdings, L.P.Beneficial shares | 1,493,740 | — | — | Sharesbeneficially ownedprior to offering; Number |
| Vivo Innovation Fund II Holdings, L.P.Beneficial shares | 1,493,740 | — | — | Sharesbeneficially ownedafter offering; Number |
| Janus Henderson Biotech Innovation Master Fund LimitedBeneficial shares | 1,134,361 | — | — | Sharesbeneficially ownedprior to offering; Number |
| Janus Henderson Biotech Innovation Master Fund LimitedBeneficial shares | 1,134,361 | — | — | Sharesbeneficially ownedafter offering; Number |
| J. Jean Cui, Ph.D.Beneficial shares | 3,973,138 | — | — | Sharesbeneficially ownedprior to offering; Number |
| J. Jean Cui, Ph.D.Beneficial shares | 3,973,138 | — | — | Sharesbeneficially ownedafter offering; Number |
| J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliatesBeneficial ownership | — | 18.7%Beneficial | — | Sharesbeneficially ownedprior to offering; Percentage |
| J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliatesBeneficial ownership | — | 13%Beneficial | — | Sharesbeneficially ownedafter offering; Percentage |
| Entities affiliated with Cormorant Asset Management LPBeneficial ownership | — | 15.5%Beneficial | — | Sharesbeneficially ownedprior to offering; Percentage |
| Entities affiliated with Cormorant Asset Management LPBeneficial ownership | — | 10.8%Beneficial | — | Sharesbeneficially ownedafter offering; Percentage |
| OrbiMed Private Investments VIII, LPBeneficial ownership | — | 9.8%Beneficial | — | Sharesbeneficially ownedprior to offering; Percentage |
| OrbiMed Private Investments VIII, LPBeneficial ownership | — | 6.8%Beneficial | — | Sharesbeneficially ownedafter offering; Percentage |
| Vivo Innovation Fund II Holdings, L.P.Beneficial ownership | — | 7%Beneficial | — | Sharesbeneficially ownedprior to offering; Percentage |
| Vivo Innovation Fund II Holdings, L.P.Beneficial ownership | — | 4.9%Beneficial | — | Sharesbeneficially ownedafter offering; Percentage |
| Janus Henderson Biotech Innovation Master Fund LimitedBeneficial ownership | — | 5.3%Beneficial | — | Sharesbeneficially ownedprior to offering; Percentage |
| Janus Henderson Biotech Innovation Master Fund LimitedBeneficial ownership | — | 3.7%Beneficial | — | Sharesbeneficially ownedafter offering; Percentage |
| J. Jean Cui, Ph.D.Beneficial ownership | — | 18.7%Beneficial | — | Sharesbeneficially ownedprior to offering; Percentage |
| J. Jean Cui, Ph.D.Beneficial ownership | — | 13%Beneficial | — | Sharesbeneficially ownedafter offering; Percentage |
| Y. Peter Li, Ph.D., MBABeneficial shares | 3,973,138 | — | — | Sharesbeneficially ownedprior to offering; Number |
| Y. Peter Li, Ph.D., MBABeneficial shares | 3,973,138 | — | — | Sharesbeneficially ownedafter offering; Number |
| Geoff Oxnard, M.D.Beneficial shares | 75,861 | — | — | Sharesbeneficially ownedprior to offering; Number |
| Geoff Oxnard, M.D.Beneficial shares | 75,861 | — | — | Sharesbeneficially ownedafter offering; Number |
| Jason Keyes, MBABeneficial shares | 54,818 | — | — | Sharesbeneficially ownedprior to offering; Number |
| Jason Keyes, MBABeneficial shares | 54,818 | — | — | Sharesbeneficially ownedafter offering; Number |
| Sundeep Agrawal, M.D.Beneficial shares | 589,195 | — | — | Sharesbeneficially ownedprior to offering; Number |
| Sundeep Agrawal, M.D.Beneficial shares | 589,195 | — | — | Sharesbeneficially ownedafter offering; Number |
| Bihua Chen, MBABeneficial shares | 3,301,534 | — | — | Sharesbeneficially ownedprior to offering; Number |
| Bihua Chen, MBABeneficial shares | 3,301,534 | — | — | Sharesbeneficially ownedafter offering; Number |
| Carl L. Gordon, Ph.D., CFABeneficial shares | 2,089,279 | — | — | Sharesbeneficially ownedprior to offering; Number |
| Carl L. Gordon, Ph.D., CFABeneficial shares | 2,089,279 | — | — | Sharesbeneficially ownedafter offering; Number |
| Y. Peter Li, Ph.D., MBABeneficial ownership | — | 18.7%Beneficial | — | Sharesbeneficially ownedprior to offering; Percentage |
| Y. Peter Li, Ph.D., MBABeneficial ownership | — | 13%Beneficial | — | Sharesbeneficially ownedafter offering; Percentage |
| Sundeep Agrawal, M.D.Beneficial ownership | — | 2.8%Beneficial | — | Sharesbeneficially ownedprior to offering; Percentage |
| Sundeep Agrawal, M.D.Beneficial ownership | — | 1.9%Beneficial | — | Sharesbeneficially ownedafter offering; Percentage |
| Bihua Chen, MBABeneficial ownership | — | 15.5%Beneficial | — | Sharesbeneficially ownedprior to offering; Percentage |
| Bihua Chen, MBABeneficial ownership | — | 10.8%Beneficial | — | Sharesbeneficially ownedafter offering; Percentage |
| Carl L. Gordon, Ph.D., CFABeneficial ownership | — | 9.8%Beneficial | — | Sharesbeneficially ownedprior to offering; Percentage |
| Carl L. Gordon, Ph.D., CFABeneficial ownership | — | 6.8%Beneficial | — | Sharesbeneficially ownedafter offering; Percentage |
| All directors and executive officers as a group (11 persons)Beneficial ownership | — | 48.4%Beneficial | — | Sharesbeneficially ownedprior to offering; Percentage |
| All directors and executive officers as a group (11 persons)Beneficial ownership | — | 33.7%Beneficial | — | Sharesbeneficially ownedafter offering; Percentage |
| Sheila Gujrathi, M.D.Beneficial shares | 90,160 | — | — | Sharesbeneficially ownedprior to offering; Number |
| Sheila Gujrathi, M.D.Beneficial shares | 90,160 | — | — | Sharesbeneficially ownedafter offering; Number |
| John Schmid, MBABeneficial shares | 67,620 | — | — | Sharesbeneficially ownedprior to offering; Number |
| John Schmid, MBABeneficial shares | 67,620 | — | — | Sharesbeneficially ownedafter offering; Number |
| All directors and executive officers as a group (11 persons)Beneficial shares | 10,371,004 | — | — | Sharesbeneficially ownedprior to offering; Number |
| All directors and executive officers as a group (11 persons)Beneficial shares | 10,371,004 | — | — | Sharesbeneficially ownedafter offering; Number |
| common stockper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; common stock; non-cumulative voting; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained |
Source and calculation ↗
Source statement; >; source predicate: owned; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group, no exercise of the underwriters’ option to purchase additional shares of our common stock and no exercise of outstanding options other than the Exercised Option Share Issuance); source scope: of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately; not an additive ownership partition
Upon the closing of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately 41.8% of our outstanding common stock (based on the number of shares of our common stock outstanding as of March 31, 2026 and assuming no purchase of shares in this offering by any of this group, no exercise of the underwriters’ option to purchase additional shares of our common stock and no exercise of outstanding options other than the Exercised Option Share Issuance). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders, and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock. Any of these actions could adversely affect the market price of our common stock.
Source statement; approximately ; source predicate: will, in the aggregate, hold; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group, no exercise of the underwriters’ option to purchase additional shares of our common stock and no exercise of outstanding options other than the Exercised Option Share Issuance); source scope: of our outstanding common stock (based on the number of shares of our common stock outstanding as of March 31, 2026 and assuming no purchase of shares in this offering by any of this group, no exerci; not an additive ownership partition
Upon the closing of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately 41.8% of our outstanding common stock (based on the number of shares of our common stock outstanding as of March 31, 2026 and assuming no purchase of shares in this offering by any of this group, no exercise of the underwriters’ option to purchase additional shares of our common stock and no exercise of outstanding options other than the Exercised Option Share Issuance). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders, and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock. Any of these actions could adversely affect the market price of our common stock.
Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates(1)
Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates(1)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Entities affiliated with Cormorant Asset Management LP(2)
Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Entities affiliated with Cormorant Asset Management LP(2)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: OrbiMed Private Investments VIII, LP(3)
Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: OrbiMed Private Investments VIII, LP(3)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Vivo Innovation Fund II Holdings, L.P.(4)
Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Vivo Innovation Fund II Holdings, L.P.(4)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Janus Henderson Biotech Innovation Master Fund Limited(5)
Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Janus Henderson Biotech Innovation Master Fund Limited(5)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: J. Jean Cui, Ph.D.(1)
Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: J. Jean Cui, Ph.D.(1)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates(1)
Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates(1)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: Entities affiliated with Cormorant Asset Management LP(2)
Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: Entities affiliated with Cormorant Asset Management LP(2)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: OrbiMed Private Investments VIII, LP(3)
Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: OrbiMed Private Investments VIII, LP(3)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: Vivo Innovation Fund II Holdings, L.P.(4)
Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: Vivo Innovation Fund II Holdings, L.P.(4)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: Janus Henderson Biotech Innovation Master Fund Limited(5)
Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: Janus Henderson Biotech Innovation Master Fund Limited(5)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: J. Jean Cui, Ph.D.(1)
Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: J. Jean Cui, Ph.D.(1)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Y. Peter Li, Ph.D., MBA(1)
Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Y. Peter Li, Ph.D., MBA(1)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Geoff Oxnard, M.D.(6)
Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Geoff Oxnard, M.D.(6)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Jason Keyes, MBA(7)
Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Jason Keyes, MBA(7)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Sundeep Agrawal, M.D.(8)
Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Sundeep Agrawal, M.D.(8)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Bihua Chen, MBA(9)
Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Bihua Chen, MBA(9)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Carl L. Gordon, Ph.D., CFA(10)
Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Carl L. Gordon, Ph.D., CFA(10)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: Y. Peter Li, Ph.D., MBA(1)
Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: Y. Peter Li, Ph.D., MBA(1)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: Sundeep Agrawal, M.D.(8)
Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: Sundeep Agrawal, M.D.(8)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: Bihua Chen, MBA(9)
Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: Bihua Chen, MBA(9)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: Carl L. Gordon, Ph.D., CFA(10)
Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: Carl L. Gordon, Ph.D., CFA(10)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: All directors and executive officers as a group (11 persons)(14)
Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: All directors and executive officers as a group (11 persons)(14)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Sheila Gujrathi, M.D.(11)
Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Sheila Gujrathi, M.D.(11)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: John Schmid, MBA(12)
Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: John Schmid, MBA(12)
Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: All directors and executive officers as a group (11 persons)(14)
Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition
Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: All directors and executive officers as a group (11 persons)(14)
Literal source per-share voting entitlement; common stock; non-cumulative voting; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained
Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of stockholders, except as otherwise expressly provided in our amended and restated certificate of incorporation or required by applicable law. There are no cumulative voting rights. Source context: Upon the filing of our amended and restated certificate of incorporation and the closing of this offering, our authorized capital stock will consist of 700,000,000 shares of our common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. All of our authorized preferred stock upon the closing of this offering will be undesignated. The following is a summary of the rights of our common and preferred stockholders and some of the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the closing of this offering, respectively, and of the Delaware General Corporation Law (DGCL). This summary is not complete. For more detailed information, please see our amended and restated certificate of incorporation and amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant provisions of the DGCL.
Saved control snapshot
The dated saved report retains its own figures and assumptions. These strings are not new calculation inputs.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Existing holdersMajor ownership group | — | ~69.4%* | — | |
| Other disclosed classesMajor ownership group | — | See filing | — | |
| IPO sharesPublic / new investors | — | 9.375M | — |
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
IPO shares are immediately tradable; later supply depends on the final lock-up, option and resale-registration terms.
- Initial float
- 9.375M
- Restricted / potential supply
- 30.64M
- Multiple
- See filing
- Increase
- See filing
Share supply
Source lock-up conditions
Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| WeAfter date of this prospectus · Source conditions apply | 180 days |
| our directors, our officers and substantially all of the holders of our common stock or securities convertible into, exercisable for, or exchangeable for our common stockAfter date of this prospectus · Source conditions apply | 180 days |
| Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties)After date of this prospectus · Source conditions apply | 180 days |
Source and calculation
We have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of our common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of our common stock or such other securities, in cash or otherwise), in each case without the prior written consent of the representatives for a period of 180 days after the date of this prospectus, other than the shares of our common stock to be sold in this offering.
SEC lock-up paragraph; source 1726871:1728068; SHA256 3ea74a57fdc13795fe958e943e03da473d45bde16e628d8f6147fa81b5e6eec4 ↗Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares of our common stock, could reduce the market price of our common stock. After this offering, we will have 30,643,660 shares of common stock outstanding (assuming no exercise of the underwriters’ option to purchase additional shares of our common stock). This includes the shares that we are selling in this offering, which may be resold in the public market immediately without restriction, unless purchased by our affiliates. Substantially all of the remaining 21,268,660 shares of our common stock initially will be restricted as a result of securities laws, market standoff provisions or lock-up agreements, but will become eligible to be sold after this offering as described in the section titled “Shares eligible for future sale.” We, our directors, our officers and substantially all of the holders of our common stock or securities convertible into, exercisable for, or exchangeable for our common stock have entered into market standoff agreements with us and have entered or will enter into lock-up agreements under which we have agreed or will agree, subject to specific exceptions described in the section titled “Underwriting,” not to offer, sell, or transfer such securities for 180 days following the date of this prospectus. We refer to such period as the lock-up period. The underwriters may, in their sole discretion and at any time or from time to time before the termination of the lock-up period release all or any portion of the securities subject to lock-up agreements.
SEC lock-up paragraph; source 616114:618119; SHA256 9d2f9e293a170c8b33690af4a5864674d3365c0365bfe3c10d6d3b96c1b6b43b ↗Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties) have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 180 days after the date of this prospectus (such period, the restricted period), may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of the representatives, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock (including,
SEC lock-up paragraph; source 1730330:1731394; SHA256 37b6a51c29f7cefa63fe107ccf4ad1738116e37e2966d8168a6b8b8128a7da60 ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
Milestones and unconfirmed releases
| Holder / event | Term / date | Conditions |
|---|---|---|
| Over-allotment window | Post-listing See filing · Additional shares only if exercised | Over-allotment window · Additional shares only if exercised |
| Insider resale eligibility | Holder-specific See 424B · Existing-holder supply | Insider resale eligibility · Existing-holder supply |
Basis and evidence
Over-allotment window · Additional shares only if exercised
Lock-up / shares eligible for future sale ↗Insider resale eligibility · Existing-holder supply
Lock-up / shares eligible for future sale ↗Financial quality
Bars compare absolute amounts within each measure. Each measure has its own scale.
Net income / (loss)
$ · Annual values as reportedOperating cash flow
$ · Annual values as reported| Calculation | FY2024 | FY2025 |
|---|---|---|
| Net income / (loss) | ($30,695,000) | ($60,555,000) |
| Operating cash flow | ($31,416,000) | ($46,925,000) |
| Calculation | Reported value |
|---|---|
| Cash and cash equivalents2024-12-31 | $100,147,000 |
| Cash and cash equivalents2025-12-31 | $136,682,000 |
| Current assets2024-12-31 | $104,172,000 |
| Current assets2025-12-31 | $138,826,000 |
| Total assets2024-12-31 | $106,775,000 |
| Total assets2025-12-31 | $162,968,000 |
| Current liabilities2024-12-31 | $6,773,000 |
| Current liabilities2025-12-31 | $15,480,000 |
| Total liabilities2024-12-31 | $6,773,000 |
| Total liabilities2025-12-31 | $37,873,000 |
| Total equity / (deficit)2024-12-31 | ($72,883,000) |
| Total equity / (deficit)2025-12-31 | ($131,728,000) |
| General and administrative expensesFY2024 | $4,591,000 |
| General and administrative expensesFY2025 | $7,886,000 |
| Cash and cash equivalents2025-12-31 · Unaudited | $136,682,000 |
| Cash and cash equivalents2026-03-31 · Unaudited | $116,003,000 |
| Current assets2025-12-31 · Unaudited | $138,826,000 |
| Current assets2026-03-31 · Unaudited | $119,723,000 |
| Total assets2025-12-31 · Unaudited | $162,968,000 |
| Total assets2026-03-31 · Unaudited | $143,410,000 |
| Current liabilities2025-12-31 · Unaudited | $15,480,000 |
| Current liabilities2026-03-31 · Unaudited | $16,178,000 |
| Total liabilities2025-12-31 · Unaudited | $37,873,000 |
| Total liabilities2026-03-31 · Unaudited | $38,707,000 |
| Total equity / (deficit)2025-12-31 · Unaudited | ($131,728,000) |
| Total equity / (deficit)2026-03-31 · Unaudited | ($152,120,000) |
| General and administrative expenses3M ended 2025-03-31 · Unaudited | $1,882,000 |
| General and administrative expenses3M ended 2026-03-31 · Unaudited | $2,206,000 |
| Net income / (loss)3M ended 2025-03-31 · Unaudited | ($10,478,000) |
| Net income / (loss)3M ended 2026-03-31 · Unaudited | ($21,008,000) |
| Operating cash flow3M ended 2025-03-31 · Unaudited | ($10,979,000) |
| Operating cash flow3M ended 2026-03-31 · Unaudited | ($20,940,000) |
Basis and evidence
Saved snapshot — period not verified
These saved figures have no verified reporting period or currency basis. They are excluded from statement comparisons and calculations.
Financial quality
| Calculation | Reported value |
|---|---|
| Revenue | Pre-revenue |
| Net resultLatest reported | $(71.09M) |
| Market-value referencePost-listing snapshot | $501.94M |
| Shares outstandingLatest reported | 30.64M |
| Offer size9.375M | $150.00M |
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Financial review | Reported financial figures are shown above. A cash-runway estimate needs compatible cash-flow and funding assumptions. Open filing ↗ |
Baseline filing — comparison pending
No source-comparable material changes identified in this report.
Why it mattersChanges dilution, public float and potential supply.
Evidence · 424B4 · 2026/08/07Why it mattersChanges valuation, proceeds and first-day return assumptions.
Evidence · 424B4 · 2026/08/07424B4
• Final prospectus source verified
• Trading began on 2026-08-07 at $16.00
Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.
- Potential impact
- High
- Evidence
- 424B4 · 2026/08/07 ↗
The latest reported period remains loss-making.
- Potential impact
- High
- Evidence
- 424B4 · 2026/08/07 ↗
The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.
- Potential impact
- High
- Evidence
- 424B4 · 2026/08/07 ↗
Option exercise, employee equity and lock-up expiry can expand tradable supply.
- Potential impact
- Medium
- Evidence
- 424B4 · 2026/08/07 ↗
Sources and calculation notes
Final prospectus, offer price, listing date and headline financial evidence reconciled
View the filing's actual first page +
